Summary

• CDI is a prevalent and concerning infection that is on the rise
• Fidaxomicin is recommended over oral vancomycin for the treatment if CDI given potential for decreased recurrence
  • Oral vancomycin remains an acceptable alternative

Literature supporting adjunctive therapies, including bezlotoxumab,  prophylaxis, and FMT are promising, but require additional investigation